Novel antibody-based therapeutics have revolutionised healthcare and are a prominent feature on top-selling pharmaceutical lists. As antibody engineering and manufacturing technologies improve, previously untreatable diseases can be targeted with increased speed and efficiency. Creating a pathway that balances cost, speed and risk for therapeutic antibody development is crucial to successful and timely approval of new therapeutics.

Author: by Lonza

You may also be interested in:
Mammalian
Bispecific Antibody
Difficult to Express Proteins
Monoclonal Antibody
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
UC-II Active Lifestyles eBook
Infographic
UC-II® undernatured type II collagen: key trends in the evolving active lifestyle market
Explore the future of the joint health market, and keep consumers of all ages moving the way they...
product hero image
White paper
Exploring the Need for Dose-Flexible Manufacturing
Bringing a new drug to market is a complex journey, often involving various dosage forms throughout...
Building momemtum_QA_DEC24
Article
Expert Q&A: Partnering for Success in the Supplement Market
Explore how Lonza's innovative platform and visionary approach to partnership empowers brands with a...
AI-Enabled Route Scouting Service Scientists
Webinar (on-demand)
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
Developing innovative medicines often involves intricate small-molecule APIs with lengthy synthetic...
Webinar (on-demand)
Charting a Successful CMC Journey for Your ADC Drug Product
Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their...
ADC vial with gradient background - close crop
Interview
Expert Q&A: Accelerate Your ADC Journey
Filling the Need for Integrated Bioconjugate Solutions Antibody drug conjugates (ADCs) are...
KC Video thumbnail
Video
mRNA and LNP Encapsulation Capabilities at our Geleen/NL Center of Excellence
Discover how our team, with its impressive mRNA/LNP track record, can help you progress your...
Mammalian Biologics Drug Substance Manufacture MC1
Article
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be...
capsule image
White paper
Bridging the Gaps in Oral Dosage Research: 4 Focus Areas Highlighted by the UNGAP network
As our designated center of excellence for novel drug delivery systems, Innovaform™ Accelerator is...
Video
CAR-T Cells on the Fast Lane: From T-cell Selection to CAR-T Cell Drug Product in Just 3 Days
In this presentation, we explore the rapid growth of the CAR T market, driven by oncology...
Used as thumbnail for Powder to Particles podcast.
White paper
Unlocking the Potential of Carrier-Based Formulations: A Process Optimization Guide
Carrier-based formulations are commonly used in drug delivery systems, particularly in inhalation...
Webinar (on-demand)
Early Preclinical Development of mRNA/LNP Projects, Transitioning Successfully to cGMP...
View our on-demand webinar exploring the development steps that lead to an mRNA construct optimized...